Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

GSK Jumps On Report Elliott Has Built Up Multibillion-Pound Stake In Firm

Published 15/04/2021, 13:08
Updated 15/04/2021, 13:09
© Reuters.

© Reuters.

By Dhirendra Tripathi

Investing.com – Shares of GlaxoSmithKline (NYSE:GSK) were higher by 6% in Thursday’s premarket following a report by Financial Times that hedge fund Elliott Management has built up a multibillion-pound stake in the pharma giant.

The news has sent the shares soaring after three years under the stewardship of Emma Walmsley, in which the shares have steadily underperformed vis-a-vis major rivals such as AstraZeneca (NASDAQ:AZN) and Pfizer (NYSE:PFE

Walmsley last year unveiled plans to break up the company by separating the consumer health business from its pharma and vaccine division, which has failed to deliver in the race to find a treatment for Covid-19.

The FT didn't report any details of what changes Elliott, known for its activism, might press for.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.